Український радіологічний та онкологічний журнал,
Journal Year:
2024,
Volume and Issue:
32(4), P. 504 - 517
Published: Dec. 3, 2024
Background.
Lung
cancer
continues
to
be
a
significant
health
concern
globally.
Due
the
heterogeneity
of
disease,
using
innovative
strategies
for
effective
management
and
treatment
patients
is
extremely
important.
Purpose
–
characterize
mutational
profile
group
non-small
cell
lung
(NSCLC)
utilizing
next-generation
sequencing
technique.
Materials
Methods.
A
total
42
samples
that
were
fixed
in
formalin
embedded
paraffin
(FFPE)
collected
from
Ukrainian
diagnosed
with
who
had
surgery
at
Sumy
Regional
Clinical
Oncology
Center.
DNA
was
extracted
FFPE
Omega
Bio-tek
E.Z.N.A.®
Kit
(USA)
following
manufacturerʼs
instructions.
Sequencing
performed
on
Illumina
NextSeq
550Dx
platform
550
Mid-Output
Kit.
The
Cancer
Genome
Atlas
Program
(TCGA)
database
(https://portal.gdc.cancer.gov/)
used
comparative
analysis
prevalence
genomic
mutations
cohort
Caucasian
NSCLC.
Statistical
Stata
V.18.0
software
(StataCorp,
Texas,
USA;
https://www.stata.com;
2024).
paper
belongs
«description
case
series»
category
which
type
study
recognized
by
evidence
based
medicine
does
not
claim
statistical
significance
result.
Results.
Among
NSCLC
samples,
11
(26.19%)
carried
driver
such
as
EGFR
(n=2;
L858R),
KRAS
(n=7;
G12C,
G12D,
G12A
A146S),
BRAF
(n=1;
V600E)
translocation
EML4(exon6)
ALK
(exon20)
chr2:42503838
chr2:29447579).
All
mutually
exclusive.
No
NRAS,
ROS1,
RET,
MET,
ERBB2,
PIK3CA
mutation
cases
detected.
number
never
smoked
significantly
higher
than
former
or
current
smokers
(p=0.046).
association
found
between
age,
sex,
tumor
stage,
histology
NSCLC,
mutations.
Conclusions.
Molecular
genetic
profiling
revealed
26.19%
radically
treated
Most
are
oncogenic
sensitive
tyrosine
kinase
inhibitors.
Molbank,
Journal Year:
2025,
Volume and Issue:
2025(1), P. M1958 - M1958
Published: Jan. 24, 2025
The
target
compound,
N4-(3-chloro-4-fluorophenyl)-7-((4-methoxybenzyl)thio)quinazoline-4,6-diamine,
was
synthesized
in
two
steps
from
N-(3-chloro-4-fluorophenyl)-7-fluoro-6-nitroquinazolin-4-amine
by
a
nucleophilic
aromatic
substitution,
yielding
N-(3-chloro-4-fluorophenyl)-7-((4-methoxybenzyl)thio)-6-nitroquinazolin-4-amine
which
characterized
1H
NMR,
13C
19F
and
HRMS.
Subsequent
reduction
yielded
the
molecule,
N4-(3-chloro-4-fluorophenyl)-7-((4-methoxybenzyl)thio)quinazoline-4,6-diamine.
structure
of
compound
confirmed
HSQC,
HMBC,
HRMS,
FTIR.
RSC Medicinal Chemistry,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 1, 2025
A
series
of
2
H
-[1,4]oxazino[2,3-
f
]quinazolin
derivatives
were
synthesized.
Compound
4a
suppressed
cell
proliferation,
colony
formation,
invasion
and
migration,
induced
G0/G1
phase
arrest
in
T790M
mutant
H1975
cells.
Journal of Oncology Research and Therapy,
Journal Year:
2024,
Volume and Issue:
9(2)
Published: May 9, 2024
Abstract
Non-small
cell
lung
cancer
(NSCLC)
remains
a
prevalent
and
deadly
malignancy,
presenting
substantial
global
health
challenge.
Significant
progress
has
been
achieved
in
the
last
few
decades
regarding
comprehension
of
complex
molecular
mechanisms
that
underlie
NSCLC.
This
extensive
literature
review
analyzes
present
understanding
pathways
associated
with
non-small
emphasizes
potential
targeting
as
favorable
therapeutic
approach.
We
conduct
detailed
analysis
key
targets
discuss
impact
emerging
modalities
on
treatment
landscape
Furthermore,
we
explore
avenues
for
future
research
this
rapidly
advancing
field,
emphasizing
importance
ongoing
innovation
managing
NSCLC
precision
medicine.
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(14), P. 7508 - 7508
Published: July 9, 2024
Third-generation
tyrosine
kinase
inhibitors
are
the
first-line
gold
standard
in
treating
advanced
non-small-cell
lung
cancer
bearing
common
EGFR
mutations,
but
data
documenting
clinical
efficacy
uncommon
mutations
currently
limited.
In
this
paper,
we
describe
case
of
a
patient
compound
exon
20,
who
experienced
near-complete
response
to
third-line
Osimertinib,
with
metabolic
complete
pulmonary,
nodal
and
ostheolytic
lesions.
This
radiological
assessment
corresponded
an
ECOG
PS
improvement
(from
three
one)
substantial
benefit
for
patients.
Out
two
S768I
was
associated
poor
third-generation
TKI
V774M
had
unknown
significance,
highlighting
complexity
correct
management
these
kinds
mutations.
We
reviewed
literature
document
up-to-date
preclinical
concerning
treatment
patients
Cancers,
Journal Year:
2024,
Volume and Issue:
16(15), P. 2766 - 2766
Published: Aug. 5, 2024
Non-small
cell
lung
cancer
(NSCLC)
presents
a
variety
of
druggable
genetic
alterations
that
revolutionized
the
treatment
approaches.
However,
identifying
new
may
broaden
group
patients
benefitting
from
such
novel
options.
Recently,
interest
focused
on
neuregulin-1
gene
(NRG1),
whose
fusions
have
become
potential
predictive
factor.
To
date,
occurrence
NRG1
has
been
considered
negative
prognostic
marker
in
NSCLC
treatment;
however,
many
premises
remain
behind
targetability
signaling
pathways
affected
by
gene.
The
role
ErbB-mediated
proliferation
especially
seems
to
be
as
main
target
treatment.
Hence,
harboring
benefit
targeted
therapies
pan-HER
family
inhibitors,
which
shown
efficacy
previous
studies
various
cancers,
and
anti-HER
monoclonal
antibodies.
Considering
increased
clinical
target,
following
review,
we
highlight
its
biology,
well
implications
were
evaluated
clinics
or
remained
under
consideration
trials.
